-
Home
SOP Information
SOPs and Supporting Information – alphabetic listing
Q to Z
Retinal Vascular Occlusion F059
Rulebase for retinal vascular occlusive disease
- Smoking tobacco products - material contribution
Retinal vascular occlusive disease - Smoking tobacco products - material contribution Factor
Last reviewed for CCPS 05 October 2006.
Investigative Documents
Claimant Report - Smoking [CRD905]
Claimant Report - Smoking [CRV905]
Preliminary questions [36276]
the veteran has smoked cigarettes, cigars or pipe tobacco at some time.36299 — the veteran has established the causal connection between smoking tobacco products and VEA service for the clinical onset of retinal vascular occlusive disease.
36300 — the veteran has established the causal connection between smoking tobacco products and operational service for the clinical onset of retinal vascular occlusive disease.
or
36301 — the veteran has established the causal connection between smoking tobacco products and eligible service for the clinical onset of retinal vascular occlusive disease.
Clinical onset and operational service [36300]
the veteran smoked at least fifteen pack years of cigarettes or the equivalent thereof in other tobacco products before the clinical onset of retinal vascular occlusive disease and, where smoking has ceased, the clinical onset of retinal vascular occlusive disease occurred within 30 years of cessation. smoking as a causal result of operational service made a material contribution to the Statement of Principles requirements for the clinical onset of retinal vascular occlusive disease.Clinical onset and eligible service [36301]
the veteran smoked at least 20 pack years of cigarettes or the equivalent thereof in other tobacco products before the clinical onset of retinal vascular occlusive disease and, where smoking has ceased, the clinical onset of retinal vascular occlusive disease occurred within 30 years of cessation. smoking as a causal result of eligible service made a material contribution to the Statement of Principles requirements for the clinical onset of retinal vascular occlusive disease.